Experience

Davis Polk advised the representatives of the underwriters in connection with an initial public offering of Inventiva S.A.’s 7,478,261 American Depositary Shares. Aggregate gross…

Davis Polk advised Centogene N.V. on its $49 million follow-on public offering of 3,500,000 of its common shares, consisting of 2,000,000 common shares offered by Centogene and 1,500,000…

Davis Polk advised the initial purchasers in connection with the offering by Oleoducto Central S.A. (OCENSA) of $500 million aggregate principal amount of its 4.000% notes due 2027…

Davis Polk advised the underwriters in connection with a public offering of 6,900,000 shares of common stock of Revolution Medicines, Inc. at $26.00 per share (which includes the…

Davis Polk advised the joint lead managers in connection with Mizuho Financial Group, Inc.’s SEC-registered takedown offering of senior notes, which consisted of $1.1 billion aggregate…

Davis Polk advised Rumo Luxembourg S.à r.l., as issuer, and Rumo S.A., as guarantor, in connection with Rumo Luxembourg’s $500 million offering of 5.250% senior notes due 2028, which were…

Davis Polk advised the initial purchasers in connection with a $170 million Regulation S offering by Golden Wheel Tiandi Holdings Limited of its 14.250% senior notes due 2023. Golden Wheel…

Davis Polk advised the underwriters in the initial public offering of Ocumension Therapeutics on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule…

Davis Polk advised Outotec Oyj as to U.S. law in connection with the demerger by Metso Corporation’s minerals business by way of transfer (without liquidation of Metso) to Outotec and…

Davis Polk advised Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering…